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Abstract
Objectives: To assess how girls’ preferences have changed almost 3 years after the much debated start of the human
papillomavirus (HPV) vaccination program.
Methods: A discrete choice experiment (DCE) was conducted among girls aged 11–15 years who were invited, or were not
yet invited, to get vaccinated. A panel latent class model was used to determine girls’ preferences for vaccination based on
five characteristics: degree of protection against cervical cancer; duration of protection; risk of mild side-effects; age of
vaccination; and the number of required doses of the vaccine.
Results: The response rate was 85% (500/592). Most girls preferred vaccination at age 14 years (instead of at age 9 years)
and a 2-dose scheme (instead of the current 3-dose scheme). Girls were willing to trade-off 7% (CI: 3.2% to 10.8%) of the
degree of protection to have 10% less risk of mild side-effects, and 4% (CI: 1.2% to 5.9%) to receive 2 doses instead of 3
doses. Latent class analyses showed that there was preference heterogeneity among girls, i.e., higher educated girls and
HPV vaccinated girls had a higher probability to opt for HPV vaccination at a higher age than lower educated girls or non-
vaccinated girls.
Conclusions: Three years after the start of HPV vaccination program the risk of mild side-effects and age at vaccination
seem to have become less important. For the Dutch national immunization program, we recommend not to lower the
current target age of 12 years. A 2-dose scheme may result in a higher uptake and we recommend that if this scheme is
introduced, it needs to receive adequate publicity.
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Introduction
Human Papillomavirus (HPV) infection is a necessary factor in
the development of cervical cancer [1,2]. HPV types 16 and 18 are
responsible for about 70% of all cervical cancers worldwide [3].
Preferably the HPV vaccine (which protects against those two
types) is given prior to the initiation of sexual activity, because the
degree of protection is reduced after HPV infection [4–6].
Many Western countries have included HPV vaccination in
their immunization program. For example, the United Kingdom,
Canada, Australia and the Netherlands offer the HPV vaccine to
girls at an age between 11 and 14 years; in these countries, the
uptake rates range from 50–80%. The willingness to accept HPV
vaccination can largely be influenced by general preferences for
healthcare interventions [7]. One way to assess preferences is to
conduct a discrete choice experiment (DCE), in which people
trade off risks and benefits among competing programs [8]. In the
design of a DCE it is assumed that a healthcare intervention can
be described by its characteristics (attributes) and that the levels of
those attributes determine preferences for an intervention [9]. By
offering a series of choices between two or more intervention
alternatives with different combinations of attribute levels, the
relative importance of attributes can be assessed [10]. Previous
DCE studies about preferences for HPV vaccination showed that
attributes such as the duration and degree of protection against
cervical cancer were important among mothers of eligible girls
[11], adults from the general public [12], and eligible girls [13].
In the Netherlands, the bivalent HPV vaccine is offered free of
costs to 12-year-old girls by sending a personal invitation. These
girls do not need their parents’ permission when deciding about
uptake. Since the introduction of the vaccine in the Netherlands in
2009, uptake rates increased from 52% in 2009 [14] to 59% in
2011 [15]. The introduction of the program coincided with an
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intensive societal debate involving politics, physicians, media,
parents and girls, which may have resulted in uptake rates being
lower than expected beforehand. During that period we carried
out a DCE to assess girls’ preferences for HPV vaccination [13].
We showed how girls made trade-offs between the degree of
protection against cervical cancer, the duration of protection, the
risk of serious side-effects (e.g. hospitalization), the risk of mild side-
effects (e.g. nausea), and age of vaccination. Currently, almost 3
years later, although no serious side-effects have been linked to the
vaccine, this has not resulted in a large increase in the vaccination
rates.
Therefore, the present study assesses which attributes of HPV
vaccination have influenced preferences for HPV vaccination
uptake after the media debates have ended and in the absence of
reports of serious side-effects. To our knowledge, this is the first
study to compare preferences for HPV vaccination as expressed in
DCEs. We will look at the differences in preferences as measured
in 2009 versus 2011. This comparison may provide insight into
girls’ motivation to be vaccinated or not, how this motivation can
change over time, and how to improve dissemination of
information about the vaccine.
Methods
Attributes and attribute levels
The selection of HPV vaccination attributes and their levels was
based on our previous study [13]. However, for the present study
we excluded the attribute ‘risk of serious side-effects’ from the
choice sets since no serious side-effects of the vaccine have been
reported since its introduction in vaccination campaigns. The
Centers for Disease Control and Prevention (CDC) state the
following about the bivalent vaccine: the bivalent vaccine is safe, it
has been in use around the world for several years and has been
very safe. However, any medicine can potentially cause a serious
problem, such as a severe allergic reaction. The risk of a vaccine
causing a serious injury, or death, is extremely small. Life-
threatening allergic reactions from vaccines are very rare [16].
Instead, we mentioned in the questionnaire that the risk of serious
side-effects on the long term is unknown. We added the attribute
‘number of doses of the vaccine’, because less than the currently
applied number of 3 doses is also likely to be effective [17].
The final set consisted of the following attributes: 1) the degree
of protection against cervical cancer; 2) the duration of protection;
3) the risk of mild side-effects; 4) the age of vaccination; and 5) the
number of doses of the vaccine (Table 1). The levels we used for
degree of protection were 50%, 70% and 90%. It is assumed that
the protection against cervical cancer is 70%, but since it takes 10
to 15 years for cervical cancer to develop it is not sure yet whether
the protection indeed will be 70%. It might also be possible that
the protection is lower or a new HPV vaccine will be available in
the future that has an effectiveness of 90% [18]. Since to date,
follow-up data on HPV vaccinated young women are available for
8.4 years, it is known that protection lasts at least 8 years, but it is
unknown how long the duration of protection will be [19]. We
therefore wanted to know girls’ preferences for a duration of 8
years, 25 years and lifelong protection. The levels of the risk of
mild side-effects were 1:30, 10:30 and 20:30, which were based on
figures from the Centers for Disease Control and Prevention [20].
We choose 30 as the denominator, because many classes consist of
30 students and therefore girls could interpret the risk as 1, 10 or
20 students in their class suffering from mild side-effects. The side-
effects were defined as: pain, itch, redness and swelling on the
injection area; fever; headache; dizziness; nausea and fainting
within 2 hours after vaccination. The risk of mild side-effects is not
modifiable, but if for example girls put a lot of weight on this risk,
information about the risk may highlight the short duration of the
side-effects. Levels of the age of vaccination were 9, 12 and 14
years. If most girls will have a preference for 9 or 14 years instead
of the current 12 years, it might be a possibility to broaden the age
range at which girls are offered the vaccine for free. The levels of
the number of doses of the vaccine were 2 and 3 doses. If for
example most girls have a preference for 2 doses, then uptake may
increase if 2 doses are used instead of 3.
Study design
The combination of four attributes with three levels each, and
one attribute with two levels, resulted in 162 (34621) hypothetical
HPV vaccination alternatives. We generated a subsample of these
alternatives using priors available from De Bekker-Grob et al. [13]
and a zero prior for the attribute ‘number of doses’ to generate an
efficient design by maximizing D-efficiency (using Ngene software,
version 1.1.1, http://www.choice-metrics.com/) [21]. Sixteen
choice sets were constructed to be able to estimate all main
effects. Choice sets consisted of two HPV vaccination alternatives
and a ‘no HPV vaccination’ option to allow respondents to ‘opt
out’ (Table 2).
Study sample
Calculation of the optimal sample size for estimating discrete
choice models from DCE data is complicated, as it depends on the
true values of the unknown parameters estimated in the choice
models [22]. Earlier studies have shown that sample sizes of 300–
400 respondents are sufficient for reliable statistical analyses
[23,24]. Therefore, first, we strived to collect at least 400
completed questionnaires. In order to do so, taking into account
an expected response rate of at least 80% [13], we recruited a
representative sample of n= 592 girls aged 11–15 years through
four secondary schools in urban and rural areas in the Nether-
lands. Second, we checked a posteriori whether our sample size
would be sufficient to find significant differences for each attribute
(level) at a 5% level using the true values of the estimated
parameters and NGene software (http://www.choice-metrics.
com/).
Questionnaire
The first page of the questionnaire provided basic information
about HPV vaccination. Next, respondents were asked to indicate
per choice set which option appealed to them most. Pictographs
were used to illustrate the percentages of the degree of protection
and the risk of mild side-effects.
To assess respondents’ understanding of the DCE task we
included a dominant choice set as a rationality test. In this choice
set age of vaccine administration was similar in both alternatives,
while one alternative was characterized by logically preferable
levels on all other attributes. Also we included four items on a 5-
point Likert scale to evaluate whether respondents considered the
DCE questions ‘clear-unclear, ‘difficult-easy’, ‘annoying-pleasant’,
and the number of questions as ‘too many-not too many’.
Convergent validity was checked by asking the respondents to rank
the five attributes of HPV vaccination from most important to
least important. This ranking is compared with the trade-offs
respondents were willing to make between the degree of protection
and the other attributes.
The questionnaire used in our 2009 study was pilot tested to
check for face validity and for problems in interpretation (n= 16).
Because the number of attributes are the same as in the present
study and only the attribute ‘risk of serious side-effects’ is replaced
with ‘number of doses of the vaccine’, we did not expect problems
Change in Preferences of Girls for HPV Vaccination
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in interpretation and therefore did not pilot test the questionnaire
of the present study.
Procedure
Respondents completed the questionnaire in the classroom or
auditorium during school time. First, general information was
given about HPV and vaccination and about the way DCE
questions should be completed. Completion of the written
questionnaire lasted about 20–30 min. Questionnaires were
completed in November and December 2011.
Beforehand, girls’ parents had received an information letter
covering the purpose, the voluntary nature and anonymity of the
study, and an opt-out form. Parents that did not want their
daughter to participate could sign the opt-out form. Girls’ parents
who approved participation did not have to sign an informed
consent form. The Medical Ethics Committee of Erasmus MC,
University Medical Center Rotterdam declared that this research
(number MEC 2011-059) did not fell under the Medical Research
Involving Human Subjects Act, because Participants were not
subject to procedures or are required to follow rules of behavior.
Statistical analyses
The DCE was analyzed by taking each choice among the three
options (two HPV vaccination options, and a ‘no vaccination
option’) as an observation. The utility for ‘‘no vaccination’’ was
normalized to zero: V(no vaccination) = 0. Using NLogit software
(http://www.limdep.com/), the observations were analysed by a
panel latent class model [25]. This model can be used to identify
classes in the population, i.e., identifying different utility (prefer-
ence) functions across unobserved subgroups. Class membership is
latent in that each respondent belongs to each class up to a
modelled probability and is not deterministically assigned by the
analyst a priori. The model is flexible in that the probability that
sampled respondents belong to a particular class can be linked to
covariates (such as age, education, etc.), hence allowing for some
understanding as to the make-up of the various class segments
[26]. Panel latent class model means that the model accounts for
the pseudo panel nature of the DCE data since each respondent
completed 16 choice tasks. To determine the number of classes to
impose on the model structure, we selected the model with the best
fit based on the Akaike information criterion (AIC) [25].
We tested a number of different specifications for the utility
(preference) function. After testing for linear continuous effects of
the attributes, the following final specification of the utility model
was estimated:
VDc~b0Dczb1DcEFFECTIVENESSzb2DcDURATION 25Y
zb3DcDURATION LIFETIMEzb4DcSIDE{EFFECTS
zb5DcAGE 12Yzb6DcAGE 14Yzb7DcNUMBER OF
DOSES 3
ð1Þ
V|c represents the observable utility (preference score) that
respondents belonging to class segment c have for an HPV
vaccination. b1|c27|c are class specific coefficients of the attributes
indicating the relative weight individuals place on a certain
attribute (level). The unobserved component, E, is assumed to be
independently and identically (IID) extreme value type 1 (EV1)
distributed. In addition to the utility function, the final model
allowed for several significant covariates (‘respondent’s history of
HPV vaccination’ and ‘education’) to enter into the class
assignment model. Effects coded variables were used for protection
of duration, age at vaccination, and doses of the vaccine. Degree of
protection and risk of mild side-effects were coded as a linear term.
The statistical significance of a coefficient (p-value #0.05)
indicates that conditional to belonging to a class, respondents
differentiated between one attribute (or attribute level) and
another in making stated choices about HPV vaccination
Table 1. Attributes and levels for HPV vaccination included in the discrete choice experiment design.
Attributes Levels
Degree of protection against cervical cancer (%) 50, 70, 90
Duration of protection (years) 8, 25, lifetime
Risk of mild side-effects 1:30, 10:30, 20:30
Age at vaccination (years) 9, 12, 14
Number of doses of the vaccine 2, 3
doi:10.1371/journal.pone.0104772.t001
Table 2. Choice set example.
Attributes Program A Program B No vaccination
Degree of protection against cervical cancer 70% 90% 0%
Duration of protection Lifetime 8 years n.a.
Risk of mild side-effects 10:30 20:30 No risk
Age at vaccination 12 years 12 years n.a.
Number of doses of the vaccine 3 3 0
Which vaccination program do you prefer? A B None
n.a. = not applicable.
doi:10.1371/journal.pone.0104772.t002
Change in Preferences of Girls for HPV Vaccination
PLOS ONE | www.plosone.org 3 August 2014 | Volume 9 | Issue 8 | e104772
programs. A priori, we expected all attributes to be significant.
The sign of a coefficient reflects whether the attribute has a
positive or negative effect on the preference score (utility). We
expected that the attributes ‘risk of mild-effects’ and ‘the number
of doses of the vaccine’ would have a negative effect. The value of
each coefficient represents the relative importance respondents
assign to an attribute level. Sensitivity analyses were conducted to
explore the impact of excluding respondents who failed the
rationality test by excluding their data from the sample and re-
running the analysis [27,28].
In terms of the class assignment parameters, statistically
significant parameter estimates indicate that the associate covar-
iate (i.e. ‘respondent’s history of HPV vaccination’ and ‘educa-
tion’) can be used to help in understanding the different segments.
For example, if the education parameter associated with a
particular class in the assignment model is positive and significant,
then this is indicative that people who have a higher educational
level are more likely to belong to that particular class and, hence,
have preferences associated with the utility function belonging to
that class as given in Equation (1).
The trade-offs respondents were willing to make between the
attributes were calculated by the ratios of the coefficients of the
different attributes with the degree of protection as the denom-
inator. These trade-offs were weighted by the probability that a
respondent belongs to a given class. Confidence intervals were
calculated in Excel using the Krinsky and Robb method [29]. The
number of simulations was 65,000 (i.e., 130 Sobol draws6500
respondents).
Since our 2009 study is a point of reference for this study, we
compared the similarity of the present sample to the 2009 sample.
Mann-Whitney U tests were used for continuous variables and
Chi-square tests were used for categorical variables.
Results
Respondents
The response rate was 85% (500/592). The mean age of the
respondents was 12.9 years; most had a higher level of secondary
education (38%) and no religious affiliation (68%). Of the
respondents, 63% had already been invited to get vaccinated
against HPV of whom 70% had opted for vaccination (Table 3).
Compared to the 2009 sample, respondents in the present sample
were younger (difference 0.4 years, p-value,0.01); more respon-
dents had a lower or intermediate educational level and less girls
had a higher educational level (p-value,0.01); and less respon-
dents were vaccinated against HPV (p-value = 0.045).
DCE results
Based on the AIC criterion, three classes were identified
(Table 4). The average class probabilities within the sampled
population were 31.0%, 45.5% and 23.5% for latent class 1, 2 and
3, respectively. The probability to belong to a specific class
depended on the respondent’s level of secondary education and
whether she has been vaccinated against HPV. Namely, girls
attending higher levels of secondary education and HPV
vaccinated girls had a higher chance to belong to latent class 3,
than lower educated and non HPV vaccinated girls(Dutch
secondary schools have different educational levels). Respondents
belonging to latent class 3 preferred vaccination at age 12 years to
age 9 years, which was not a significant preference for respondents
who belong to latent class 1 and 2. Most of the estimated
coefficients for each latent class had the expected sign and were
significant in most cases (Table 4). Although all five HPV
vaccination attributes significantly influenced girls’ preferences,
the preference heterogeneity was substantial. Respondents in all
classes preferred a lower risk of mild side-effects and a higher
degree of protection to a higher risk and a lower degree of
protection; they also preferred 25 years of protection to 8 years of
protection. Respondents belonging to class 1 preferred 25 years of
protection to 8 years of protection, rather than lifetime protection
to 8 years of protection. Respondents who belong to latent class 2
and 3 preferred 2 doses to 3 doses, and preferred vaccination at 14
years rather than at 9 years, whereas respondents belonging to
latent class 1 showed no significant preference for the number of
doses or the age of vaccination. Sensitivity analyses showed that
excluding the data of ten out of 500 respondents (2%) who ‘failed’
the rationality test had no relevant impact on the size or relative
importance of the attributes.
Trade-offs
Overall, respondents were willing to trade-off 7% (CI: 3.2% to
10.8%) of the degree of protection to have a 10% less risk of mild
side-effects. To obtain protection against HPV for 25 years instead
of 8 years, they were willing to trade-off 18% (CI: 8.6% to 29.6%),
and to obtain lifetime protection instead of 8 years of protection,
they were willing to trade-off 21% (CI: 20.1% to 37.2%).
Respondents were willing to trade-off 4% (CI: 1.2% to 5.9%) to
receive 2 doses instead of 3 doses. To get a vaccination at age 12 or
14 years, instead of at 9 years, respondents were willing to trade-off
4% (CI: 22.4% to 8.6%) and 8% (CI: 20.6% to 16.7%),
respectively (Table 5).
DCE rationality
The dominant choice set was answered correctly by 490/500
(98%) of the respondents; 83 respondents completed the ranking
test incorrectly (e.g. giving the same rank to multiple attributes)
and were excluded from this ranking analyses. The most
important attributes according to the ranking test were: the
degree of protection (70%); the duration of protection (17%); the
risk of mild side-effects (8%); the number of doses (4%); and the
age of vaccination (2%) (n = 407). The trade-offs respondents were
willing to make between the degree of protection and the other
attributes indicated the following order of importance of attributes:
duration of protection, followed by the risk of mild side-effects, the
number of doses of the vaccine, and age at vaccination (Table 5).
Thus, the ranking test supports the convergent validity of the DCE
results.
The mean evaluations of the DCE questions were (range 1–5):
‘unclear-clear’ (M=3.48, SD=1.14), ‘difficult-easy’ (M=3.53,
SD=1.14), ‘annoying-pleasant’ (M=2.82, SD=1.01), and ‘too
many questions-not too many questions’ (M=2.56, SD=0.93).
Discussion
We used a DCE to determine girls’ preferences for HPV
vaccination almost 3 years after the much debated start of the
HPV vaccination program. Overall, girls were willing to trade-off
18% of the degree of protection to obtain a vaccination with 25
years protection instead of 8 years protection, and trade-off 7% to
have a 10% less risk of mild side-effects. To receive 2 doses of the
vaccine instead of 3 doses, they were willing to trade-off 4% of the
degree of protection. Furthermore, it appeared that higher
educated girls and HPV vaccinated girls have a higher probability
to opt for HPV vaccination if it is offered at age 12 years instead of
at age 9 years, than girls with lower education levels or girls who
were not vaccinated.
When comparing these reported trade-offs with those of our
previous study in 2009 [13], the changes are not substantial. The
Change in Preferences of Girls for HPV Vaccination
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risk of mild side-effects became less important: in 2011 girls were
willing to trade off 7% of the degree of protection (CI: 3.2% to
10.8%) to obtain a 10% less risk of mild side-effects, while in 2009
they were willing to trade-off 18% (CI: 13.8% to 22.4%). Also, it
became less important to obtain lifetime protection instead of 8
years (in 2011) or 6 years protection (in 2009), as this trade-off was
no longer significant in 2011 (21%, CI: 20.1% to 37.2%) whereas
it was in 2009 (38%, CI 32.1% to 44.3%). Also, age of vaccination
at 12 years instead of at 9 years was no longer significant in 2011
(2011: 4%, CI: 22.4% to 8.6%; 2009: 7%, CI: 2.6% to 10.6%).
In summary, almost 3 years after initiation of the HPV
vaccination campaign on the Netherlands, the risk of mild side-
effects and age at vaccination seem to have become less important.
Potentially, the girls had a better idea about which mild side-effects
to expect and were less concerned about them. Also, the
importance of the degree of protection may have gained value
for the girls. The age of vaccination might be less of an issue in
2011 given the longer duration of protection, i.e. 8 years in 2011
compared with 6 years in 2009.
There was preference heterogeneity among the girls, i.e. higher
educated girls and HPV vaccinated girls have a higher probability
to opt for HPV vaccination if it is offered at age 12 years instead of
at age 9 years, than girls with lower education levels or girls who
were not vaccinated. Furthermore, the majority of girls (including
higher educated girls and HPV vaccinated girls) also preferred
vaccination at age 14 years to vaccination at age 9 years. In other
words, most girls did not prefer vaccination at the age of 9 years.
Overall, girls were willing to trade-off 3.5% of the degree of
protection to receive 2 doses instead of 3 doses, and most girls also
preferred a 2-dose scheme to the current 3-dose scheme. Recently,
the Netherlands National Institute for Public Health and the
Environment decided that a 2-dose scheme will be introduced,
because 2 doses are found to provide as much protection as 3 doses
as long as the vaccination is given before girls turn 15 years of age
[30,31]. Since we showed that girls preferred a 2-dose scheme, this
new strategy may result in a higher vaccination uptake. We want
to stress that this revised vaccination program needs to receive
adequate publicity. Surprisingly, it seems that some girls preferred
25 years of protection to lifetime protection. The concept of
‘lifetime’ might be too vague for these young girls and they may be
unable to correctly judge its value; a protection period of 25 years
might be interpreted by them as a very long period and it may
sound more ‘concrete’.
A strength of the present study is the large number of
respondents (n = 500) and the high response rate (85%). A
limitation might be that we did not include protection against
genital warts as an attribute.
In conclusion, this study shows that, almost 3 years after the
much debated start of the HPV vaccination program in the
Netherlands, trade-offs that girls are willing to make have not
Table 3. Characteristics of the study respondents (n = 500).
Characteristics
Mean (SD)
Age (years) 12.9 (0.96)
range 11–15
N (%)
Educational level
Low 145 (29.1)
Intermediate 164 (32.9)
High 189 (38.0)
Religion
None 338 (68.0)
Christian 124 (24.9)
Muslim 28 (5.6)
Other 7 (1.4)
Country of birth
The Netherlands 472 (99.0)
Country of birth of parents
Both parents in the Netherlands 385 (79.9)
One parent outside the Netherlands 42 (8.7)
Both parents outside the Netherlands 55 (11.4)
HPV vaccination
Invited to get vaccinated against HPV 311 (62.7)
HPV vaccinated 220 (70.7)
Intention if not yet invited:
Low 20 (10.9)
Neutral 31 (16.8)
High 133 (72.3)
doi:10.1371/journal.pone.0104772.t003
Change in Preferences of Girls for HPV Vaccination
PLOS ONE | www.plosone.org 5 August 2014 | Volume 9 | Issue 8 | e104772
changed substantially. The risk of mild side-effects and age at
vaccination still influenced the girls’ preferences, but seem to have
become less important. This study shows that there was preference
heterogeneity among the girls, with higher educated girls and
HPV vaccinated girls having a higher probability to opt for HPV
vaccination at a higher age, than girls with lower education levels
or girls who were not vaccinated. Also, since most of the girls
preferred vaccination at age 14 years to vaccination at age 9 years,
we recommend not to lower the current target age of 12 years in
national immunization program in countries such as the Nether-
lands, Denmark, Sweden, Norway and United Kingdom. We also
recommend to introduce a 2-dose scheme (instead of the current
3-dose scheme), because the girls are far from indifferent to the
choice between 2 and 3-dose scheme.
Table 4. Respondents’ preferences for HPV vaccination based on a panel latent class model.
Latent Class 1 Latent Class 2 Latent Class 3
Attribute Coeff. Coeff. Coeff.
Risk of mild side-effects (per 10%) 20.49 *** 20.41 *** 20.30 ***
Degree of protection against cervical
cancer (per 10%)
1.33 *** 0.40 *** 0.73 ***
Duration of protection:
8 years (reference) 20.50 20.81 20.89
25 years 0.84 *** 0.29 *** 20.19 ***
Lifetime 20.34 ** 0.52 *** 1.07 ***
Age at vaccination:
9 years (reference) 0.05 20.29 20.32
12 years 20.12 20.01 0.16 ***
14 years 0.07 0.30 *** 0.16 ***
Number of doses of the vaccine:
2 doses (reference) 0.14 0.10 0.08
3 doses 20.14 * 20.10 *** 20.08 **
Constant 24.39 *** 1.73 *** 24.98 ***
Class probability model
Constant 20.0851 0.3705 ** -
Higher eduction 20.0007 ** 20.0005 * -
Vaccinated 20.0005 * 20.0005 * -
Class probability (%)
Average class probability 31.0 45.5 23.5
Model fits
Log-likelihood 24.545.47
Pseudo R-squared 0.481
Notes: (1) ***, **, * denotes significance at 1%, 5%, and 10%, respectively; (2) Effects coded variables used for protection duration, age at vaccination, and doses of the
vaccine; (3) Coeff. = coefficient; (4) number of observations = 7,976.
doi:10.1371/journal.pone.0104772.t004
Table 5. Respondents’ trade-offs between degree of protection versus various aspects of a vaccination program as used in the
present study.
Change in levels Willingness to trade degree of protection
% (CI)
Per 10% less risk of mild side-effects 6.7 (3.2 to 10.8)
A protection duration of 25 years instead of 8 years 17.8 (8.6 to 29.6)
A lifetime protection instead of 8 years 21.4 (20.1 to 37.2)
A vaccination at age 12 years instead of 9 years 4.4 (22.4 to 8.6)
A vaccination at age 14 years instead of 9 years 8.2 (20.6 to 16.7)
A vaccination program consisting of 2 instead of 3 doses 3.5 (1.2 to 5.9)
Note: CI = 95% confidence interval based on the Krinsky Robb method adjusted for class probabilities.
doi:10.1371/journal.pone.0104772.t005
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